Drug Profile
Research programme: parasitic disease therapeutics - sanofi aventis/DNDi
Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Sanofi
- Developer Drugs for Neglected Diseases Initiative Foundation; Sanofi
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported African trypanosomiasis; Helminthiasis; Leishmaniasis; Schistosomiasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in African trypanosomiasis in Europe
- 30 May 2011 Early research in African trypanosomiasis in Europe (unspecified route)